SCHEMBL802027

SCHEMBL802027

Cc1ccccc1-c1cc(Nc2n[nH]c3ccccc23)cc(-c2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 3/20 0.46
TRPA1 O75762 1/20 0.46
GRM4 Q14833 6/20 0.45
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALPL P05186 1/20 0.38
GAA P10253 1/20 0.38
IDO1 P14902 1/20 0.38
HPGD P15428 1/20 0.38
TTK P33981 1/20 0.38
MAPK10 P53779 1/20 0.38
ADRA2A P08913 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801694 0.88 VCP (0.43) FADS1TRPA1GRM4GSK3AGSK3B
SCHEMBL802326 0.88 FADS1 (0.48) FADS1TRPA1GRM4LMNATP53
SCHEMBL801635 0.88 FADS1 (0.49) FADS1GRM4GSK3AGSK3BMAPT
SCHEMBL802028 0.86 TRPA1 (0.52) FADS1TRPA1GRM4GSK3BLMNA
SCHEMBL12619783 0.83 FADS1 (0.46) FADS1TRPA1GRM4LMNATP53
SCHEMBL802064 0.83 GSK3A (0.42) FADS1TRPA1GRM4GSK3AGSK3B
SCHEMBL802348 0.83 FADS1 (0.40) FADS1TRPA1GRM4GSK3AGSK3B
SCHEMBL802068 0.82 FADS1 (0.41) FADS1TRPA1GRM4ADRA2ACYP1A2
SCHEMBL802337 0.81 GRM4 (0.45) FADS1TRPA1GRM4GSK3BLMNA
SCHEMBL802674 0.80 GSK3A (0.44) FADS1TRPA1GRM4GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 FADS1 3442/4885TRPA1 4786/4885GRM4 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.